Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-12-11
2009-12-29
Jeffrey, Stucker (Department: 1648)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S228100, C424S093100
Reexamination Certificate
active
07638499
ABSTRACT:
Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
REFERENCES:
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4486530 (1984-12-01), David et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4818540 (1989-04-01), Chien et al.
patent: 4873191 (1989-10-01), Wagner et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4950647 (1990-08-01), Robins et al.
patent: 4965188 (1990-10-01), Mullis
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5290678 (1994-03-01), Jackowski
patent: 5322770 (1994-06-01), Gelfand
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5371017 (1994-12-01), Houghton et al.
patent: 5372928 (1994-12-01), Miyamura et al.
patent: 5412087 (1995-05-01), McGall et al.
patent: 5585258 (1996-12-01), Houghton et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5597691 (1997-01-01), Houghton et al.
patent: 5604105 (1997-02-01), Jackowski
patent: 5670152 (1997-09-01), Weiner et al.
patent: 5670153 (1997-09-01), Weiner et al.
patent: 5679342 (1997-10-01), Houghton et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5698390 (1997-12-01), Houghton et al.
patent: 5710008 (1998-01-01), Jackowski
patent: 5712087 (1998-01-01), Houghton et al.
patent: 5712088 (1998-01-01), Houghton et al.
patent: 5712145 (1998-01-01), Houghton et al.
patent: 5714596 (1998-02-01), Houghton et al.
patent: 5728520 (1998-03-01), Weiner et al.
patent: 5744358 (1998-04-01), Jackowski
patent: 5747274 (1998-05-01), Jackowski
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5766845 (1998-06-01), Weiner et al.
patent: 5767097 (1998-06-01), Tam
patent: 5847101 (1998-12-01), Okayama et al.
patent: 5856437 (1999-01-01), Miyamura et al.
patent: 5863719 (1999-01-01), Houghton et al.
patent: 5871903 (1999-02-01), Miyamura et al.
patent: 5879904 (1999-03-01), Brechot et al.
patent: 5885799 (1999-03-01), Houghton et al.
patent: 5932556 (1999-08-01), Tam et al.
patent: 5942234 (1999-08-01), Ralston et al.
patent: 5959092 (1999-09-01), Miyamura et al.
patent: 5968775 (1999-10-01), Houghton et al.
patent: 5989905 (1999-11-01), Houghton et al.
patent: 6027729 (2000-02-01), Houghton et al.
patent: 6056961 (2000-05-01), Lavie et al.
patent: 6060068 (2000-05-01), Doyle et al.
patent: 6063380 (2000-05-01), Chedid et al.
patent: 6063772 (2000-05-01), Tam
patent: 6071693 (2000-06-01), Cha et al.
patent: 6074816 (2000-06-01), Houghton et al.
patent: 6074846 (2000-06-01), Ralston et al.
patent: 6074852 (2000-06-01), Ralston et al.
patent: 6096541 (2000-08-01), Houghton et al.
patent: 6130326 (2000-10-01), Ramasamy et al.
patent: 6150087 (2000-11-01), Chien
patent: 6150337 (2000-11-01), Tam
patent: 6153421 (2000-11-01), Yanagi et al.
patent: 6171782 (2001-01-01), Houghton et al.
patent: 6190864 (2001-02-01), Cha et al.
patent: 6194140 (2001-02-01), Houghton et al.
patent: 6214583 (2001-04-01), Cha et al.
patent: 6235888 (2001-05-01), Pachuk et al.
patent: 6274148 (2001-08-01), Ralston et al.
patent: 6297370 (2001-10-01), Cha et al.
patent: 6303292 (2001-10-01), Weiner et al.
patent: 6312889 (2001-11-01), Houghton et al.
patent: 6514731 (2003-02-01), Valenzuela et al.
patent: 6541011 (2003-04-01), Punnonen et al.
patent: 6555114 (2003-04-01), Leroux-Roels et al.
patent: 6653125 (2003-11-01), Donnelly et al.
patent: 6680059 (2004-01-01), Sallberg et al.
patent: 6960569 (2005-11-01), Sallberg
patent: 7022830 (2006-04-01), Sallberg
patent: 7223743 (2007-05-01), Sallberg
patent: 7226912 (2007-06-01), Sallberg
patent: 7307066 (2007-12-01), Sallberg
patent: 7439347 (2008-10-01), Sallberg
patent: 2002/0004048 (2002-01-01), Ralston et al.
patent: 2002/0165172 (2002-11-01), Sallberg et al.
patent: 2002/0183508 (2002-12-01), Maertens et al.
patent: 2002/0187945 (2002-12-01), Tam
patent: 2003/0007977 (2003-01-01), Wheeler et al.
patent: 2003/0008274 (2003-01-01), Maertens et al.
patent: 2003/0032005 (2003-02-01), Maertens et al.
patent: 2003/0044774 (2003-03-01), Valenzuela et al.
patent: 2003/0064360 (2003-04-01), Maertens et al.
patent: 2004/0092730 (2004-05-01), Sallberg
patent: 0 388 232 (1990-09-01), None
patent: 0 414 475 (1991-02-01), None
patent: 0 450 931 (1996-06-01), None
patent: 0 543 924 (1997-06-01), None
patent: 0 842 947 (1998-05-01), None
patent: 0 693 687 (1999-07-01), None
patent: 0 556 292 (1999-12-01), None
patent: 1 034 785 (2000-09-01), None
patent: 0 318 216 (2001-08-01), None
patent: 0 398 748 (2002-01-01), None
patent: WO 90/15070 (1990-12-01), None
patent: WO 91/15575 (1991-10-01), None
patent: WO 92/10092 (1992-06-01), None
patent: WO 92/19743 (1992-11-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 93/06126 (1993-04-01), None
patent: WO 94/11530 (1994-05-01), None
patent: WO 94/12305 (1994-06-01), None
patent: WO 94/16737 (1994-08-01), None
patent: WO 95/11995 (1995-05-01), None
patent: WO 96/09805 (1996-04-01), None
patent: WO 96/28162 (1996-09-01), None
patent: WO 96/33739 (1996-10-01), None
patent: WO 97/12043 (1997-04-01), None
patent: WO 97/26883 (1997-07-01), None
patent: WO 97/29212 (1997-08-01), None
patent: WO 97/31256 (1997-08-01), None
patent: WO 97/47358 (1997-12-01), None
patent: WO 98/16184 (1998-04-01), None
patent: WO 98/16186 (1998-04-01), None
patent: WO 98/30223 (1998-07-01), None
patent: WO 98/34640 (1998-08-01), None
patent: WO 98/37180 (1998-08-01), None
patent: WO 99/04008 (1999-01-01), None
patent: WO 99/28482 (1999-06-01), None
patent: WO 00/44388 (2000-08-01), None
patent: WO 01/38360 (2001-05-01), None
patent: WO 01/96875 (2001-12-01), None
patent: WO 02/13855 (2002-02-01), None
patent: WO 02/14362 (2002-02-01), None
patent: WO 03/031588 (2003-04-01), None
patent: WO 2004/048402 (2004-06-01), None
U.S. Appl. No. 08/008,342, filed Jan. 26, 1993, Weiner et al.
U.S. Appl. No. 08/029,336, filed Mar. 11, 1993, Weiner et al.
U.S. Appl. No. 08/125,012, filed Sep. 21, 1993, Weiner et al.
U.S. Appl. No. 08/221,579, filed Apr. 1, 1994, Carrano et al.
AASLD Abstracts 940, “Hepatitis C Virus NS5A Sequence Configuration does not Predict Response to Induction Interferon Plus Ribavirin,” Hepatology, p. 394A (2000).
Abrignani et al., “Perspectives for a vaccine against hepatitis C virus,” Journal of Hepatology, 31: (suppl. 1):259-263 (1999).
Andre et al., “Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage,” Journal of Virology, 72(2):1497-1503(1998).
Bartenschlager et al., “Substrate Determinants for Cleavage in cis and in trans by the Hapatitis C Virus NS3 Proteinase,”Journal of Virology, pp. 198-205, (1995).
Bitter et al.,Methods in Enzymol., 153:516-544 (1987).
BLASTN 2.2.9., May 1, 2004.
Chang et al.,Ailment Pharmacol Ther. (2002) 16(9):1623-1632.
Chen et al., “Detection of Hepatitis C Virus RNA in the Cell Fraction of Saliva Before and After Oral Surgery,”J. Med. Virol., 43:223-226 (1995).
Chen et al., “Human and Murine Antibody Recognition is Focused on the ATPase/Helicase, but not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein,”Hepatology, 28(1):219-224 (1998).
Chiang et al., “Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2,”Vaccine Strategies Against Microbial Pathogens, 42.11-42.16, p. A949 (2000).
Colberre-Garapin, et al., “A new dominant hybrid selective marker for higher eukaryotic cells,”J. Mol. Biol. 150:1 (1981).
Cote et al., “Generation of human monoclonal antibodies reactive with cellular antigens”Proc Natl. Acad. Sci., 80:2026-2030 (1983).
Cotonat et
Jeffrey Stucker
Knobbe Martens Olson & Bear LLP
Li Bao Qun
Tripep AB
LandOfFree
Hepatitis C virus codon optimized non-structural NS3/4A... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis C virus codon optimized non-structural NS3/4A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus codon optimized non-structural NS3/4A... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4148129